<DOC>
	<DOCNO>NCT00412217</DOCNO>
	<brief_summary>This two-arm study compare efficacy safety erlotinib ( Tarceva ) versus placebo participant resect head neck squamous cell cancer receive concurrent chemoradiotherapy radiotherapy alone . Participants randomize receive either erlotinib 150 milligram ( mg ) orally ( PO ) daily placebo 1 year disease progression unacceptable toxicity .</brief_summary>
	<brief_title>A Study Erlotinib ( Tarceva ) Participants With Resected Head Neck Squamous Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adults great equal ( â‰¥ ) 18 year age Curatively treat head neck squamous cell cancer T3T4 and/or N2N3 pathology , without finding poor prognosis extranodal extension , positive resection margin , perineural vascular involvement Eastern Cooperative Oncology Group ( ECOG ) status 0 2 Macroscopic residual disease surgery Previous treatment antiepidermal growth factor receptor ( antiEGFR ) target therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>